ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
0.955
-0.039 (-3.95%)
Nov 21, 2024, 3:13 PM EST - Market closed
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
19.22M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
VSee Health | 8.06M |
Spruce Biosciences | 7.10M |
NEXGEL | 6.73M |
Pieris Pharmaceuticals | 1.35M |
Femasys | 1.26M |
Cyclo Therapeutics | 870.73K |
iBio, Inc. | 175.00K |
PMN News
- 7 days ago - ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 22 days ago - ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing - GlobeNewsWire